BGL Advises Theragenics Corporation on Merger with Juniper Acquisition Corporation

Brown Gibbons Lang & Company (BGL) today announced its client Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatments markets, completed a merger with Juniper Acquisition Corporation, an affiliate of Juniper Investment Company, LLC. BGL acted as the independent advisor to the company’s Board of Directors, and has rendered a fairness opinion in support of the transaction.

As a result of the merger, each outstanding share of common stock of the Company (other than shares held by Juniper Acquisition Corporation) was converted into the right to receive $2.20 per share in cash, and the Company has become a wholly owned subsidiary of an affiliate of Juniper. The company’s stock will no longer be publicly traded.

Theragenics has two divisions. Its Brachytherapy business is a global leader in the production of implantable devices and related disposable products that support low-dose radiation therapy for prostate cancer. Its Surgical Products business produces a broad set of devices and consumables that are used in wound closure, vascular access, and specialty needle applications.